IBD & Intestinal Disorders
News from the FDA/CDC
FDA finds increased blood clot, death risk associated with Xeljanz
The agency announced newly approved warnings and a new limitation on the approved indication for ulcerative colitis.
News
Hadlima approved as fourth adalimumab biosimilar in U.S.
Hadlima gets seven of Humira’s indications.
Conference Coverage
Are next-generation therapies for IBD ready? Are we making a difference?
A reduction in the rate of colectomy for ulcerative colitis indicates that we may be making a difference, which could be attributable to biologic...
From the AGA Journals
Atypical food allergies common in IBS
Many patients with irritable bowel syndrome have atypical food allergies and improve with appropriate elimination diets.
From the Journals
Algorithm predicts villous atrophy in children with potential celiac disease
Clinicians may now consider prescribing gluten-free diets to only the highest-risk patients, instead of all suspected cases, noting that more than...
From the Journals
Immune modulators help anti-TNF agents battle Crohn’s disease, but not UC
All published cohort studies to date have not been able to confirm a significant benefit to combination therapy in UC.
Feature
FDA warns about fecal microbiota for transplantation
The FDA notes that two immunocompromised adult patients received investigational FMT and developed infections caused by extended-spectrum beta-...
Conference Coverage
Fewer antibiotics prescribed with PCR than conventional stool testing
SAN DIEGO – Endoscopy, abdominal imaging also less common with polymerase chain reaction–based testing.
Conference Coverage
Novel oral drug shows early promise for IBD
SAN DIEGO – By the end of 8 weeks, ABX464 patients had significant endoscopic improvement.
From the Journals
AGA introduces pathway to navigate IBD care
Gastroenterology guidance addresses need for collaboration, gaps in mental health and nutrition.